Baral R, Sherrat A, Das R, Foon K A, Bhattacharya-Chatterjee M
Division of Hematology/Oncology, Department of Internal Medicine and The Barrett Cancer Center for Prevention, Treatment and Research, University of Cincinnati, OH 45267-0509, USA.
Int J Cancer. 2001 Apr 1;92(1):88-95. doi: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1148>3.0.co;2-9.
The anti-idiotypic (Id) monoclonal antibody (MAb) 520C9-6b (IgG1k), raised in syngenic mice against the murine anti-Her2/neu MAb 520C9 (Ab1), functionally mimics a human Her2/neu epitope and serves as a surrogate for the protein antigen. Immunization of allogeneic C57BL/6 mice and rabbits with 520C9-6b (Ab2) induced anti-Her2/neu-specific antibodies that react with antigen-positive SKBr3 cells by ELISA and FACS analysis. The immune sera inhibited binding between Ab1 and Ab2 and vice versa (binding of Ab2 to Ab1), indicating that it was a true anti-anti-Id (Ab3) antibody. The Ab3 sera or purified Ab3 specifically lysed Her2/neu-positive SKBr3 cells, but no significant lysis was observed in antigen-negative LS174T cells in an antibody-dependent cellular cytotoxicity assay. An Id-specific cellular immune response was also demonstrated in an in vitro lymphocyte proliferation assay. Furthermore, a panel of tumor tissues and tumor cells was screened for the presence of the Her2/neu epitope by its reactivity with Ab1 and Ab3 using immunohistochemistry and FACS analysis. Identical results were obtained using either Ab1 or Ab3 (Ab1'). The data indicated that anti-Id 520C9-6b can induce Her2/neu-specific antibody in experimental animals and may serve as a potential network antigen for the treatment of patients bearing Her2/neu-positive tumors.
抗独特型(Id)单克隆抗体(MAb)520C9-6b(IgG1k)是在同基因小鼠中针对鼠抗Her2/neu单克隆抗体520C9(Ab1)产生的,它在功能上模拟人Her2/neu表位,并作为蛋白质抗原的替代物。用520C9-6b(Ab2)对同种异体C57BL/6小鼠和兔子进行免疫,通过酶联免疫吸附测定(ELISA)和荧光激活细胞分选(FACS)分析诱导出与抗原阳性SKBr3细胞发生反应的抗Her2/neu特异性抗体。免疫血清抑制了Ab1与Ab2之间的结合,反之亦然(Ab2与Ab1的结合),表明它是一种真正的抗抗独特型(Ab3)抗体。在抗体依赖性细胞毒性试验中,Ab3血清或纯化的Ab3能特异性裂解Her2/neu阳性的SKBr3细胞,但在抗原阴性的LS174T细胞中未观察到明显的裂解。在体外淋巴细胞增殖试验中也证明了存在独特型特异性细胞免疫反应。此外,通过免疫组织化学和FACS分析,利用一组肿瘤组织和肿瘤细胞与Ab1和Ab3的反应性来筛选Her2/neu表位的存在情况。使用Ab1或Ab3(Ab1')获得了相同的结果。数据表明,抗独特型520C9-6b可在实验动物中诱导出抗Her2/neu特异性抗体,并可能作为治疗Her2/neu阳性肿瘤患者的潜在网络抗原